AI Article Synopsis
Article Abstract
The multiple myeloma SET domain (MMSET) protein is overexpressed in multiple myeloma (MM) patients with the translocation t(4;14). Although studies have shown the involvement of MMSET/Wolf-Hirschhorn syndrome candidate 1 in development, its mode of action in the pathogenesis of MM is largely unknown. We found that MMSET is a major regulator of chromatin structure and transcription in t(4;14) MM cells. High levels of MMSET correlate with an increase in lysine 36 methylation of histone H3 and a decrease in lysine 27 methylation across the genome, leading to a more open structural state of the chromatin. Loss of MMSET expression alters adhesion properties, suppresses growth, and induces apoptosis in MM cells. Consequently, genes affected by high levels of MMSET are implicated in the p53 pathway, cell cycle regulation, and integrin signaling. Regulation of many of these genes required functional histone methyl-transferase activity of MMSET. These results implicate MMSET as a major epigenetic regulator in t(4;14)+ MM.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3037745 | PMC |
| http://dx.doi.org/10.1182/blood-2010-07-298349 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Malaria parasite detection in Red Blood Cells with rouleaux formation morphology using YOLOv9.
Tissue Cell
December 2024
Department of Electronics and Computer Engineering, Faculty of Electrical Engineering, Universiti Teknologi Malaysia, Johor Bahru, Johor 81310 UTM, Malaysia.
Malaria is endemic in poverty-stricken regions of the world, and most diagnosis reveal comorbidity with other infectious diseases some of which manifest as a deformity of the structural arrangement of the Red Blood Cells (RBCs) during thin blood smear microscopy. This common occurring deformity is termed rouleaux formation, and it is the stacking together of RBCs like chains of coins. The presence of rouleaux formation indicates either a bacterial infection, connective tissue disease, chronic liver disease, multiple myeloma or diabetes among others, it is a highly common occurrence in malaria infected patients and according to the international council for standardization of hematology (ICSH), microscopists are mandated to report its presence.
View Article and Find Full Text PDFThe lifecycle and evolution of new regimens on the National Comprehensive Cancer Network Guidelines for newly diagnosed multiple myeloma.
Oncologist
December 2024
Division of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA 94158, United States.
Introduction: Prior studies have evaluated the level of evidence behind treatment options listed in the National Comprehensive Cancer Network (NCCN) guidelines, but no study has categorized the life cycle of regimens listed in the NCCN guidelines. We longitudinally assessed the life cycle for each regimen for newly diagnosed multiple myeloma. We track the date of first clinical data, the date of regimen addition to NCCN guidelines, the date phase 3 data (if performed) were reported, and the results of phase 3 trials.
View Article and Find Full Text PDFDREAMM-11, Part 2: Japanese phase I trial of belantamab mafodotin combination therapies in relapsed/refractory multiple myeloma.
Int J Hematol
December 2024
Oncology, GSK, Upper Providence, PA, USA.
DREAMM-11 (NCT03828292) was a Phase 1, open-label, dose-escalation study of belantamab mafodotin in Japanese patients with relapsed/refractory multiple myeloma (RRMM). In Part 1, belantamab mafodotin monotherapy (2.5 or 3.
View Article and Find Full Text PDFNovel insights into the circ_0003489/let-7b-5p/GLUT1 axis and its possible role in multiple myeloma.
Transpl Immunol
December 2024
Department of Pharmacy, Zhongshan Hospital Xiamen University, Xiamen 361004, Fujian, China. Electronic address:
Background: Circular RNAs (circRNAs) act as vital players in multiple myeloma (MM). Herein, we focused on the function of hsa_circ_0003489 (circ_0003489) in MM development and bortezomib (BTZ) resistance.
Methods: Relative RNA levels were detected by quantitative real-time polymerase chain reaction (qRT-PCR).
Comparison of thrombopoietin receptor agonists plus recombinant human thrombopoietin vs. recombinant human thrombopoietin alone for hematopoietic reconstruction in multiple myeloma patients undergoing autologous hematopoietic stem cell transplantation.
Transplant Cell Ther
December 2024
Xi'an Jiaotong University Second Affiliated Hospital, China.
Background: Hetrombopag is a novel thrombopoietin receptor agonist that has shown an additive effect in stimulating platelet production when combined with recombinant human thrombopoietin (rhTPO). But it remains unclear whether this combination can promote hematopoietic reconstruction after autologous stem cell transplant (ASCT).
Purpose: To compare the effect of recombinant human thrombopoietin (rhTPO) plus thrombopoietin receptor agonists (TPO-RA) versus rhTPO alone on hematopoietic recovery, adverse events, post-operative complications, and cost effectiveness in patients with newly diagnosed multiple myeloma (NDMM) undergoing autologous stem cell transplant (ASCT).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!